Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

(2012) A Shimoni et al.   BONE MARROW TRANSPLANTATION

Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children

(2012) Angelo Paci et al.   THERAPEUTIC DRUG MONITORING

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia

(2011) Stella Santarone et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience

(2011) M. A. Slatter et al.   BLOOD

Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party

(2011) J Wachowiak et al.   BONE MARROW TRANSPLANTATION

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

(2011) T. Ruutu et al.   HAEMATOLOGICA

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

(2011) Joseph Pidala et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: Pharmacokinetic application

(2011) Franciszek K. Główka et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Weight-based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results

(2011) Gérard Michel et al.   PEDIATRIC BLOOD & CANCER

High-Dose Busulfan and Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Neuroblastoma Patients

(2011) Blanca Molina et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

(2010) Eneida R. Nemecek et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring

(2010) J. Gaziev et al.   BLOOD

Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT

(2010) N Cantoni et al.   BONE MARROW TRANSPLANTATION

High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

(2010) Franciszek K Główka et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning

(2010) Jochen Casper et al.   JOURNAL OF CLINICAL ONCOLOGY

Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation

(2009) Imke H. Bartelink et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Busulfan in Hematopoietic Stem Cell Transplantation

(2009) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality in Acute Myelogenous Leukemia

(2009) James A. Russell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

(2009) Robert M. Dean et al.   BRITISH JOURNAL OF HAEMATOLOGY

Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients

(2009) F. Léger et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Busulfan in hematopoietic stem cell transplant setting

(2009) Jeannine S McCune et al.   Expert Opinion on Drug Metabolism & Toxicology

Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats

(2009) Vicky Sender et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Long‐term results of survival in patients with thalassemia major treated with bone marrow transplantation

(2008) Paolo Di Bartolomeo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients

(2008) Donatella Baronciani et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide

(2008) Christopher N. Bredeson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS

(2008) Borje S. Andersson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT

(2008) F K Główka et al.   BONE MARROW TRANSPLANTATION

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model

(2008) B Sadeghi et al.   BONE MARROW TRANSPLANTATION

Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation

(2008) Rob Cutting et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia

(2008) Jerzy Holowiecki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities

(2008) Brigit Greystoke et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients

(2008) Doreen Munkelt et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation

(2007) Imke H. Bartelink et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION